Tscan Price To Sales Ratio from 2010 to 2024

TCRX Stock  USD 4.52  0.26  6.10%   
Tscan Therapeutics Price To Sales Ratio yearly trend continues to be fairly stable with very little volatility. Price To Sales Ratio will likely drop to 17.26 in 2024. Price To Sales Ratio is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing Tscan Therapeutics' market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
18.16937489
Current Value
17.26
Quarterly Volatility
104.93855201
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tscan Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tscan Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 2.5 M, Interest Income of 6.6 M or Depreciation And Amortization of 3.4 M, as well as many indicators such as Price To Sales Ratio of 17.26, Dividend Yield of 0.0 or PTB Ratio of 2.66. Tscan financial statements analysis is a perfect complement when working with Tscan Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tscan Therapeutics Correlation against competitors.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

Latest Tscan Therapeutics' Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of Tscan Therapeutics over the last few years. Price to Sales Ratio is figured by comparing Tscan Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Tscan Therapeutics sales, a figure that is much harder to manipulate than other Tscan Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Tscan Therapeutics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tscan Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 25.77 X10 Years Trend
Slightly volatile
   Price To Sales Ratio   
       Timeline  

Tscan Price To Sales Ratio Regression Statistics

Arithmetic Mean180.23
Geometric Mean102.66
Coefficient Of Variation58.22
Mean Deviation89.62
Median241.34
Standard Deviation104.94
Sample Variance11,012
Range239
R-Value(0.76)
Mean Square Error4,927
R-Squared0.58
Significance0.0009
Slope(17.94)
Total Sum of Squares154,169

Tscan Price To Sales Ratio History

2024 17.26
2023 18.17
2022 2.75
2021 10.61

About Tscan Therapeutics Financial Statements

Tscan Therapeutics investors use historical fundamental indicators, such as Tscan Therapeutics' Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tscan Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Sales Ratio 18.17  17.26 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.